OSLO/LONDON, APRIL 7th 2021: EXACT THERAPEUTICS AS ("EXACT-Tx" or the
"Company"), a clinical stage precision medicine company utilizing Acoustic
Cluster Therapy (ACT®) across multiple therapeutic areas, today announced the
appointment of Dominic Moreland as Chief Financial Officer who will be based at
the London office of EXACT-Tx in White City.
"We are delighted to welcome Dominic to EXACT Therapeutics AS where his strong
prior experience in both finance and operations in the biopharmaceutical sector,
most recently as VP Finance at Autolus Therapeutic Plc, will be pivotal in
driving forward our organization", said Dr Rafiq Hasan, CEO of EXACT
Therapeutics AS. "Dominic joins EXACT-Tx at an exciting time as we continue to
expand our presence in the UK and progress our plans for the future development
Dominic, a chartered accountant and graduate from the London School of
Economics, built his career foundations working in audit at KPMG. He
subsequently gained experience in both finance and operations in a variety of
life sciences companies, including ICI/Zeneca, Baxter, Genzyme, two independent
businesses, Careology and the Whiteley Clinic as well as Autolus Therapeutics
plc. During this time Dominic also led the management buyout of Genzyme's
homecare business to form Careology Ltd where he was both founder and CEO.
Having successfully grown the homecare business, Careology was acquired by Medco
Health Solutions in 2010. At Autolus Therapeutics, Dominic was instrumental in
the leading both the preparation and execution of the successful IPO and NASDAQ
listing in 2018.
Dominic commented "I am excited to be joining EXACT Therapeutics as the team
continues to expand in London with the ongoing clinical development of ACT® in
the phase I ACTIVATE study. I am looking forward to working with the team as we
prepare for the future development of this innovative platform technology."
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com
For more information contact:
Dr Rafiq Hasan, CEO EXACT Therapeutics Rafiq@exact-tx.com
Richard Hayhurst/Janet Joy
Tel +44 7711 821527